Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–2 of 2 stories
Sanofi's rilzabrutinib receives FDA Breakthrough Therapy designation and orphan drug status in Japan for warm autoimmune hemolytic anemia. This recognition accelerates the development of the treatment for this rare condition.
Read full storySanofi's rilzabrutinib has received breakthrough therapy designation in the US and orphan drug status in Japan for treating warm autoimmune hemolytic anemia (wAIHA). This rare blood disorder involves the destruction of red blood cells, and rilzabrutinib is a novel oral Bruton’s tyrosine kinase inhibitor.
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.